Compugen (CGEN)
(Delayed Data from NSDQ)
$1.46 USD
0.00 (0.00%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $1.47 +0.01 (0.68%) 4:24 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CGEN 1.46 0.00(0.00%)
Will CGEN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGEN
Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?
Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?
CGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?
Strength Seen in Brainsway (BWAY): Can Its 5.3% Jump Turn into More Strength?
Other News for CGEN
Compugen Q2 2025 Earnings Preview
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian ...
Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025 | CGEN Stock News
Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive ...
Compugen (CGEN) Advances with Key Ovarian Cancer Trial | CGEN Stock News